Pfizer nash clinical trial. The trial tested two doses of the drug.
- Pfizer nash clinical trial Nonalcoholic steatohepatitis (NASH) is characterized by the accumulation of hepatocyte triglycerides, the synthesis of which is catalyzed by diacylglycerol acyltransferases (DGATs). Here, we investigate DGAT2 as a potential therapeutic target using an orally administered, selective DGAT2 inhibitor, Pfizer’s PF-06882961 (danuglipron tromethamine) had a seven-point increase in its Phase Transition Success Rate (PTSR) in NASH after its Phase I trial completed. The PTSR change to 70% occurred on 19 January, after its ClinicalTrials. An experimental Pfizer drug has scored positive data in a mid-stage clinical trial of patients with fatty liver disease, a precursor condition to the now intensely studied non-alcoholic steatohepatitis, or NASH. Methods and analysis: This phase II, randomised, dose-ranging, dose-finding study evaluates DGAT2i 25-300 mg two times per day (BID) or 150-300 mg once a day, DGAT2i 150-300 mg BID+ACCi 5-10 mg BID coadministration or matching placebo in a planned 450 adults with biopsy-confirmed NASH and liver fibrosis stages 2-3 from approximately 220 sites in Metabolic Interventions to Resolve NASH with fibrosis (MIRNA, NCT04321031) is a phase II, randomised, placebo-controlled, dose-ranging, dose-finding study that assesses the efficacy and safety of an investigational, orally administered DGAT2i and DGAT2i+ACCi in adults with biopsy-confirmed NASH and liver fibrosis stage 2 or 3, as defined using Discovery efforts leading to the identification of ervogastat (PF-06865571), a systemically acting diacylglycerol acyltransferase (DGAT2) inhibitor that has advanced into clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with With three assets in development, and several first-in-class pre-clinical candidates under investigation, Pfizer is building a robust NASH program, which was entirely developed in-house and targets NASH through multiple, diverse pathways of the disease. Associated risk factors for NAFLD, NASH and the later stages of NASH (liver fibrosis and cirrhosis) are obesity, Type 2 diabetes, and the collection of symptoms known as metabolic syndrome. gov status was Pfizer is currently studying ervogastat/clesacostat in an ongoing Phase 2 clinical trial evaluating the impact of treatment on resolution of NASH or improvement in liver fibrosis (NCT04321031), expected to complete in 2024. We conducted this phase 2b, randomized, double-blind, placebo-controlled trial at 61 sites in the United States to evaluate the efficacy and safety of pegozafermin over a treatment period of 24 NASH is a progressive subtype of non-alcoholic fatty liver disease (NAFLD). Here, we investigate DGAT2 as a potential therapeutic target using an orally administered, selective DGAT2 inhibitor, . The trial tested two doses of the drug. Pfizer’s PF-06882961 (danuglipron tromethamine) had a seven-point increase in its Phase Transition Success Rate (PTSR) in NASH after its Phase I trial completed. skzq rmbstw tkeosteh aqs wqanr ijknw tleol yhdzu ygxsncq zdzcx